X. Wang

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

Z. Estrov, G. Garcia-Manero, J. Cortes, 2013, Leukemia.

C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts.

C. Sawyers, A. Friedman, E. Scott, 1999, Blood.

Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, S. Pierce, 2016, Leukemia.

Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia.

S. Strom, M. Keating, M. Keating, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymphocytic vasculitis in X-linked lymphoproliferative disease.

D. Demetrick, A. Junker, R. Tan, 2001, Blood.

Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases

S. Shen, Z. Chen, Bing Chen, 2012, Leukemia.

Toll-like receptor alterations in myelodysplastic syndrome

D. Neuberg, B. Ebert, R. Bejar, 2013, Leukemia.

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.

P. Thall, E. Estey, H. Kantarjian, 2001, Blood.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Leukemia.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

H. Kantarjian, J. Cortes, F. Ravandi, 2005 .